CDIAC to CADTH: How the pan-Canadian Oncology Drug Review (pCODR) is changing to accommodate provincial cancer agency needs Date held: March 14th, 2019 Presented by: Gerry Jeffcott, 3Sicty Public Affairs with guest panelists Louise Binder & Martine Elias Webinar Information: This webinar was hosted by Gerry Jeffcott from 3Sixty Public Affairs. He summarized some important changes that the Canadian Agency for Drugs and Technologies in
Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) Date held: March 7th, 2019 Presented by: Dr. Kelvin Chan Webinar Information: Dr. Kelvin Chan gave a short explanation on what real-world evidence (RWE) is, how they can be used in cancer care and what benefits patients can get from the real-world evidence. He will also introduce the Canadian Real-world Evidence for Value of Cancer Drugs
[OTTAWA, ON March 7th, 2019] – The Canadian Cancer Survivor Network (CCSN), a national charitable organization of cancer patients, survivors, caregivers and community partners, welcomes the Advisory Council on the Implementation of National Pharmacare’s Interim Report. CCSN is pleased to hear the Council’s acknowledgement that the current healthcare system does not provide patients and consumers timely, equitable, affordable and accessible means to medically necessary therapies.